PRGO

PERRIGO CO PLC

Healthcare | Mid Cap

$0.64

EPS Forecast

$991.2

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-12-31

Perrigo's Q2 2026: Three-S Plan Keeps Rolling as Dermacosmetics Exits the Stage

Ticker PRGO; EPS; EPS consensus; earnings surprise; revenue forecast — Perrigo Company plc reports second-quarter 2026 results from continuing operations, reaffirming its outlook amid portfolio reshaping and market headwinds.

Overview: portfolio discipline in a cautious quarter

Perrigo Company plc, listed on the NYSE as PRGO, announced its second-quarter 2026 results from continuing operations for the quarter ended June 27, 2026. The headline action is less about a dramatic swing in numbers and more about governance and portfolio discipline: the company is pushing forward with its Three-S plan—simplify, streamline, strengthen—while completing the previously signaled Dermacosmetics divestiture and continuing strategic reviews of Infant Formula and Oral Care. Management leans into market-share gains in U.S. store-brand OTC and select European brands, even as it acknowledges ongoing category softness and macroeconomic headwinds.

All In vs Core: a framework to filter the noise

The release emphasizes two lenses for evaluating performance: All In results (the entirety of the business) and Core results (the go-forward business, excluding the Infant Formula and Dermacosmetics divestiture). This bifurcated reporting is designed to help investors separate structural improvements from legacy assets. While the document excerpt doesn’t publish explicit 2Q'26 numbers in this paragraph, the framing suggests Perrigo expects the Core segment to show the underlying trajectory the company wants investors to watch as the portfolio contracts around higher-value categories.

Strategy and execution: Three-S as a live program

The Three-S plan—scope, simplify, strengthen—gets another quarter of real-world testing. Perrigo touts portfolio streamlining (notably the Dermacosmetics sale) and ongoing strategic reviews of Infant Formula and Oral Care as fuel for stronger operating performance and debt reduction. In practice, the company positions itself as a more focused consumer self-care company, chasing share gains in higher-return segments while trimming non-core exposure. If you're hunting for a crystal ball, this is its closest approach: a balance sheet bend toward steadier cash flows and a product lineup tuned for value-oriented consumers.

We continued to execute our Three-S plan in the second quarter, strengthening areas of the business within our control, improving operational performance, streamlining our portfolio, and further reducing debt.

Outlook and the EPS/revenue forecast angle

Perrigo reaffirmed its full-year 2026 outlook with the expectation of a sequentially stronger second half, underpinned by clearer drivers: the moderation of under-absorption due to lower prior-year sales volumes, more favorable category comparisons, and continued robust operational execution. The press release frames the outlook around All In versus Core performance and confirms the Dermacosmetics divestiture, but it does not publish new near-term EPS figures in this excerpt. For readers tracking EPS, you’ll want to compare the eventual EPS results against the EPS consensus and watch for any earnings surprise as Perrigo’s go-forward profitability delta (Core) versus the legacy base (All In) unfolds. On the revenue forecast, the emphasis remains on improved fundamentals and portfolio efficiency rather than a flashy top-line beat, at least in the material that accompanies this release.

From a sector perspective, Perrigo’s emphasis on market-share gains and portfolio optimization offers a template for peers navigating similar headwinds: lean into core brands, exit or consolidate non-core assets, and manage leverage so that the story isn’t a margin squeeze but a margin reallocation toward higher-value growth areas.

Risks and sector context

The company flags ongoing category softness and macroeconomic headwinds, and investors will watch whether the All In vs Core delta improves in a way that translates into tangible EPS upside or downside. Dermacosmetics has been divested, which should help the balance sheet, but the timing and magnitude of benefits to earnings and cash flow depend on the pace of debt reduction and the performance of the remaining portfolio. Currency movements, competitive dynamics in store-brand OTC, and the pace of category normalization across Europe will all influence Perrigo’s ability to meet or surpass the projected revenue forecast and earnings trajectory. In short: the optics of a cleaner, sharper business are positive; the actual numbers will decide whether the stock gets a valuation rerun or remains tethered to broader consumer-health volatility.

Key takeaways for investors

  • Perrigo reaffirms its 2026 outlook while signaling a stronger second half, hinging on favorable category comparisons and sustained operating discipline.
  • The Dermacosmetics exit, coupled with ongoing reviews of Infant Formula and Oral Care, marks a meaningful portfolio reshaping toward higher-return segments.
  • All In vs Core framing provides a lens to separate legacy performance from go-forward impact; the real test will be whether Core earnings and cash flow improve at a pace the market finds credible.
  • EPS and earnings surprise will hinge on the upcoming numbers; the narrative suggests selective strength in over-the-counter and European brands, tempered by macro headwinds and demand softness.
  • For peers in consumer self-care, Perrigo’s path underscores the value of disciplined portfolio optimization and leverage management as a potential route to compound value—even when the top line doesn’t scream.

Source: Perrigo Company plc press release, Dublin, August 5, 2026. All-In vs Core framework, portfolio divestiture, and Three-S plan in motion.